Sara Thier, PhD, MPH

The emerging treatment landscape for patients with high-risk multiple myeloma is burgeoning with new classes of drugs, novel agents, and fresh combination strategies that offer many promising and exciting options for future therapeutic approaches.

The recent approval of nivolumab in the non–small cell lung cancer setting marks a unique shift in the treatment landscape of this malignancy, one that harnesses the patient's own immune system to target the tumors. However, there are challenges in using these agents.

Immunotherapy advances are among the emerging treatment approaches that make it an exciting time for patients with melanoma and their physicians.